Published by Josh White on 9th July 2026
(Sharecast News) - AstraZeneca said on Thursday that the phase 3 CARDIO-TTRansform trial of Wainua in adults with transthyretin-mediated amyloid cardiomyopathy did not meet its primary endpoint, failing to show a statistically significant benefit against placebo on the composite measure of cardiovascular mortality and recurrent cardiovascular clinical events up to 140 weeks.